AKT 3 inhibitor
Showing 1 - 25 of >10,000
Bile Acids in Acute Insulin Resistance
Recruiting
- PI3K Gene Mutation
- +4 more
- Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
-
New York, New YorkColumbia University Medical Center
Oct 6, 2022
Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)
Recruiting
- Breast Neoplasm
- +4 more
- PIK3CA inhibitor
- +12 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jan 2, 2023
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States
Completed
- Endometrial Adenocarcinoma
- +4 more
- Akt Inhibitor MK2206
- Laboratory Biomarker Analysis
-
Boston, Massachusetts
- +6 more
Jan 13, 2022
Metastatic Breast Cancer Trial in Spain (Ipatasertib, Trastuzumab, Pertuzumab)
Recruiting
- Metastatic Breast Cancer
- Ipatasertib
- +2 more
-
Badalona, Barcelona, Spain
- +9 more
Oct 24, 2022
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic
Not yet recruiting
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
- +4 more
- Computed Tomography
- +3 more
- (no location specified)
Sep 13, 2022
Advanced Malignant Solid Tumor, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7 Trial in New Brunswick
Active, not recruiting
- Advanced Malignant Solid Neoplasm
- +9 more
- Akt Inhibitor MK2206
- Hydroxychloroquine
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Jan 25, 2023
Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Taipei City (Goserelin, Fulvestrant,
Recruiting
- Premenopausal Breast Cancer
- +2 more
- Goserelin
- +3 more
-
Taipei City, TaiwanDepartment of Oncology, National Taiwan University Hospital
Feb 7, 2023
CNS Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Houston (Akt/ERK Inhibitor ONC201,
Terminated
- Central Nervous System Lymphoma
- +6 more
- Akt/ERK Inhibitor ONC201
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Mar 30, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Canada (Laboratory Biomarker Analysis, Pharmacological
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Laboratory Biomarker Analysis
- +3 more
-
Calgary, Alberta, Canada
- +4 more
Feb 10, 2022
Breast Cancer Trial in Boston (Ipatasertib, Fulvestrant, Aromatase Inhibitor)
Recruiting
- Breast Cancer
- Ipatasertib
- +3 more
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
Oct 25, 2021
Breast Cancer, Prostate Cancer, Advanced Solid Tumors Trial in Middletown, Harrison, New York (AZD5363, Enzalutamide,
Active, not recruiting
- Breast Cancer
- +2 more
- AZD5363
- +2 more
-
Middletown, New Jersey
- +2 more
Jul 5, 2022
Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis Trial in United States (procedure, drug,
Not yet recruiting
- Colorectal Adenomatous Polyp
- +3 more
- Biopsy
- +5 more
-
Ann Arbor, Michigan
- +4 more
Jan 3, 2023
Triple Negative Breast Cancer Trial in Madison (Akt/ERK Inhibitor ONC201, Methionine-Restricted Diet)
Terminated
- Triple Negative Breast Cancer
- Akt/ERK Inhibitor ONC201
- Methionine-Restricted Diet
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Feb 11, 2022
Everolimus-containing Chemotherapy in HER2- mBC PI3K/AKT/mTOR
Completed
- Breast Cancer
- +2 more
- No intervention, it was a retrospective study.
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Sep 13, 2021
Cancer, Solid Tumors Trial in United States (Vevorisertib, Fulvestrant, Paclitaxel)
Estrogen Receptor Positive Breast Cancer Trial in United Kingdom (AZD5363, Placebo, Fulvestrant)
Active, not recruiting
- Estrogen Receptor Positive Breast Cancer
- AZD5363
- +2 more
-
Manchester, Greater Manchester, United Kingdom
- +20 more
Aug 5, 2022
Solid Tumor, Adult Trial in Seoul (TAS-117)
Completed
- Solid Tumor, Adult
-
Seoul, Korea, Republic ofSeverance Hospital, Yonsei University Health System
Apr 21, 2021
Seborrheic Keratosis Trial in Santa Tecla (SM-020)
Recruiting
- Seborrheic Keratosis
-
Santa Tecla, La Libertad, El SalvadorZepeda Dermatologia
Aug 20, 2022
Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of
Not yet recruiting
- Triple Negative Breast Cancer
- +2 more
- Everolimus
- Investigator's Choice of Chemotherapy
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 25, 2023
Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain Trial in Los Angeles, Torrance (Tart
Not yet recruiting
- Breast Cancer
- +2 more
- Tart Cherry
- Omega 3 FA (Fish Oil)
-
Los Angeles, California
- +1 more
Nov 7, 2023
Metastatic Colorectal Cancer Trial (LB-100, Azenosertib)
Not yet recruiting
- Metastatic Colorectal Cancer
- (no location specified)
Oct 31, 2023
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in
Completed
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- +35 more
- Akt inhibitor MK2206
- laboratory biomarker analysis
-
Houston, TexasM D Anderson Cancer Center
Oct 14, 2020
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,
Active, not recruiting
- Estrogen Receptor-positive Breast Cancer
- +5 more
- PI3K inhibitor BYL719
- +3 more
-
Boston, Massachusetts
- +1 more
Oct 14, 2022
Relapsed or Refractory Lymphoma Trial in Miami (Itraconazole 200 mg, Fluconazole 400 mg, Rifampin 600 mg)
Completed
- Relapsed or Refractory Lymphoma
- Itraconazole 200 mg
- +3 more
-
Miami, FloridaQPS- Miami
Jan 12, 2023